KRYS vs PCVX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KRYS · Krystal Biotech$300.88 ▲ 0.21%
PCVX · Vaxcyte$63.89 ▲ 3.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KRYS +50.8%
- PCVX +48.9%
Head to head
| Metric | KRYS | PCVX |
|---|---|---|
| Price | $300.88 | $63.89 |
| Change today | ▲ 0.21% | ▲ 3.18% |
| Market cap | $8.92B | $10.11B |
| Return, 3 months | -9.3% | +9.6% |
| Return, year to date | +22.0% | +38.5% |
| Return, 1 year | +52.0% | +53.4% |
| P/E (TTM) | 40.9 | – |
| P/B | 6.2 | 4.1 |
| P/E percentile vs own 5y | 69th | 88th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +24.1% | – |
| Net profit growth (YoY) | +42.9% | -70.7% |
| Gross margin | 94.6% | – |
| Operating margin | 44.9% | – |
| Net margin | 54.8% | – |
| Return on equity | 20.1% | -36.5% |
| Analyst target vs. price | +34.1% | +92.1% |
| Analyst buy share | 88% | 88% |
| RSI (14) | 40 | 53 |
| 30-day volatility | 46.7% | 100.2% |
| Max drawdown, 1 year | -21.8% | -28.0% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PCVX is the largest of the group by market value.
- PCVX has returned the most over the past year.
- KRYS has been the calmest stock over the last 30 days.